The present invention relates to a compound of formula (I): wherein R.sub.1 is R.sub.3-IPU and R.sub.2 is the acyloxy residue of diclofenac or naproxen, and specified by the following structures (A) wherein OHR.sub.3-IPU is selected from (B) and R.sub.4 and R.sub.5 may be the same or different selected from (C) and salts, solvates and hydrates thereof. ##STR00001## ##STR00002## ##STR00003##

The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.

The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.

Novel imidazolium salts of formula (I) are described in which R is a C.sub.1-C.sub.14 alkyl group, optionally substituted by one or more fluorine atoms, or a C.sub.2-C.sub.18 alkoxyalkyl group, R is an alkyl group containing at least 8 carbon atoms, at least 6 of which are partially or entirely fluorinated, R is hydrogen or C.sub.1-C.sub.3 alkyl, Z is an organic or inorganic anion, and Q is further defined. The compounds of formula (I) are liquid crystals over a wide temperature range, and are characterized by high conductivity, hydrophobicity and stability. These properties made them ideally suitable for use in devices based on electrochemical reactions, such as solar cells, fuel cells, electrochemical sensors, lithium batteries and capacitors, etc. ##STR00001##

Novel imidazolium salts of formula (I) are described in which R is a C.sub.1-C.sub.14 alkyl group, optionally substituted by one or more fluorine atoms, or a C.sub.2-C.sub.18 alkoxyalkyl group, R is an alkyl group containing at least 8 carbon atoms, at least 6 of which are partially or entirely fluorinated, R is hydrogen or C.sub.1-C.sub.3 alkyl, Z is an organic or inorganic anion, and Q is further defined. The compounds of formula (I) are liquid crystals over a wide temperature range, and are characterized by high conductivity, hydrophobicity and stability. These properties made them ideally suitable for use in devices based on electrochemical reactions, such as solar cells, fuel cells, electrochemical sensors, lithium batteries and capacitors, etc. ##STR00001##

Provided are a photobase generator having higher sensitivity to light than do conventional photobase generators, and a photosensitive resin composition containing the photobase generator. The present invention is a photobase generator characterized in containing a salt represented by general formula (1). (In formula (1), R.sup.1-R.sup.4 are mutually independent groups represented by general formula (2), C1-18 alkyl groups, or Ar, with at least one being a group represented by general formula (2); in formula (2), (D) is a divalent group bonded on at least one side to elemental boron, and Ar.sup.1 is the same as the aforementioned Ar; and Q.sup.+ is a monovalent onium cation.) ##STR00001##

Provided are a photobase generator having higher sensitivity to light than do conventional photobase generators, and a photosensitive resin composition containing the photobase generator. The present invention is a photobase generator characterized in containing a salt represented by general formula (1). (In formula (1), R.sup.1-R.sup.4 are mutually independent groups represented by general formula (2), C1-18 alkyl groups, or Ar, with at least one being a group represented by general formula (2); in formula (2), (D) is a divalent group bonded on at least one side to elemental boron, and Ar.sup.1 is the same as the aforementioned Ar; and Q.sup.+ is a monovalent onium cation.) ##STR00001##

Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl) imidazole and pharmaceutical compositions containing the same are provided. The present invention is a tnterpenoid compound of Formula I, or a hydrate, isomer, prodrug or pharmaceutically acceptable salt thereof: wherein one or more of R, R or R is independently a substituted or unsubstituted aryl group, heteroaryl group, cycloalkyl group or heterocyclyl group, and the remaining R groups are hydrogen. The pyridyl analogs of CD-DO-1m 1 have been developed, which are more stable in human plasma and achieve a higher concentration in target tissues such as liver, pancreas, kidney and lungs.

The present invention relates to a new method for preparation of biobased imidazolium salts and derivatives thereof; in particular, for the preparation of imidazolium hydrogenooxalate. The present invention also relates to uses of imidazolium hydrogenooxalate salts, especially as a precursor of imidazolium carboxylate compounds. The present invention also refers to a green electrochemical process providing imidazolium compounds, especially imidazolium carboxylate compounds. Especially, the invention refers to a one-compartment electrochemical cell and its use for the preparation of imidazolium carboxylate compounds of formula (II): ##STR00001##

The present invention relates to a new method for preparation of biobased imidazolium salts and derivatives thereof; in particular, for the preparation of imidazolium hydrogenooxalate. The present invention also relates to uses of imidazolium hydrogenooxalate salts, especially as a precursor of imidazolium carboxylate compounds. The present invention also refers to a green electrochemical process providing imidazolium compounds, especially imidazolium carboxylate compounds. Especially, the invention refers to a one-compartment electrochemical cell and its use for the preparation of imidazolium carboxylate compounds of formula (II): ##STR00001##